Skip to main content
search

Strategic Leadership

Sign up

Latest resources

Featured resource

Category / type

What are the most common in vitro drug-drug interaction study gaps?
What are the most common in vitro drug-drug interaction study gaps?Blog

What are the most common in vitro drug-drug interaction study gaps?

Certara drug interaction science experts share data and experimental design gaps commonly found in in vitro drug-drug interaction studies.
Everything you need to know about ILAP 2.0
Everything you need to know about ILAP 2.0White Paper

Everything you need to know about ILAP 2.0

This white paper share’s key insights on the relaunch of MHRA’s Innovative Licensing and Access Pathway (ILAP).
Protect Confidential Information in Investigational Drug Submissions
Protect Confidential Information in Investigational Drug SubmissionsBlog

Protect Confidential Information in Investigational Drug Submissions

March 20, 2025 Health regulatory agencies require pharmaceutical companies to protect study participants’ personal information (PI) within regulatory drug submissions.…
Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study
Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding studyPublication

Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study

The IMPAACT 2017/MOCHA study, a phase 1/2 multicenter trial across five countries, assessed the safety, antiviral activity, and pharmacokinetics of…

Popular resources

All resources heading

Sign up to newsletter

Why sign up? Because transforming drug development is not just our goal—it’s our obsession. If it’s yours too, then be the first to know of new insights and join us in pushing the boundaries of science.